ObjectiveTo describe metastatic pattern of uterine leiomyosarcomas (ULMS) and correlate it with clinical and histopathologic parameters.MethodsWe included 113 women (mean age, 53 years; range, 29 to 72 years) with histopathology-confirmed ULMS from 2000 to 2012. Distribution of metastases was noted from imaging by two radiologists in consensus. Predictors of development of metastases were analyzed with univariate and multivariate analysis. Impact of various clinical and histopathologic parameters on survival was compared using Log-rank test and Cox proportional hazard regression model.ResultsDistant metastases were seen in 81.4% (92/113) of the patients after median interval of 7 months (interquartile range, 1 to 21). Lung was most common site of metastases (74%) followed by peritoneum (41%), bones (33%), and liver (27%). Local tumor recurrence was noted in 57 patients (50%), 51 of whom had distant metastases. Statistically significant correlation was noted between local recurrence and peritoneal metastases (p<0.001) and between lung and other common sites of hematogeneous metastases (p<0.05). Age, serosal involvement, local recurrence, and the International Federation of Gynecology and Obstetrics (FIGO) stage were predictive factors for metastases. At the time of reporting, 65% (74/113) of the patients have died; median survival was 45 months. Stage, local recurrence, and age were poor prognostic factors.ConclusionULMS metastasizes most frequently to lung, peritoneum, bone, and liver. Local recurrence was associated with peritoneal spread and lung metastases with other sites of hematogeneous metastases. Age, FIGO stage and local recurrence predicted metastatic disease and advanced stage, older age and local recurrence predicted poor outcome.

No abstract

One of the limitations of anatomical based imaging approaches is its relative inability to identify whether specific brain functions may be compromised by the location of brain lesions or contemplated brain surgeries. For this reason, methods for identifying the regions of eloquent brain that should not be disturbed are absolutely critical to the surgeon. By accurately identifying these regions preoperatively, virtually every pre-surgical decision from the surgical approach, operative goals (biopsy, sub-total vs. gross-total resection), and the potential need for awake craniotomy with intraoperative cortical-mapping is affected. Of the many techniques available to the surgeon, functional magnetic resonance imaging (fMRI) has become the primary modality of choice due to the ability of MRI to serve as a “one-stop shop” for assessing both anatomy and functionality of the brain. Given their prevalence, brain tumors serve as the model pathology for the included discussion; however, a similar case can be made for the use of fMRI in other neurological conditions, most notably epilepsy. The value of fMRI was validated in 2007 when the Centers for Medicare and Medicaid Services (CMS) established three new current procedural terminology (CPT) codes for clinical fMRI based upon its use for pre-therapeutic planning. In this article we will discuss the specific requirements for establishing an fMRI program, including specific software and hardware requirements. In addition, the nature of the fMRI CPT codes will be discussed.